Celladon Corp Share Price Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Sales 2024 * | 25.22M 1.99B | Sales 2025 * | 32.65M 2.57B | Capitalization | 3.78M 298M |
---|---|---|---|---|---|
Net income 2024 * | -24M -1.89B | Net income 2025 * | -9M -709M | EV / Sales 2024 * | 0.15 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.12 x |
P/E ratio 2024 * |
-0.16
x | P/E ratio 2025 * |
-0.71
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 13/06/17 |
James Vollins
CMP | Compliance Officer | 55 | 12/04/23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 17/07/22 | |
Thomas Dietz
CHM | Chairman | 60 | 21/03/16 |
David Apelian
CEO | Chief Executive Officer | 59 | 13/06/17 |
1st Jan change | Capi. | |
---|---|---|
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |